Our flagship product Jeuveau® is a proprietary neurotoxin indicated to temporarily improve the look of moderate to severe frown lines in adults. For the fourth consecutive year, Jeuveau has been the fastest growing neurotoxin in the U.S.
A performance beauty company building an aesthetics portfolio of consumer brands in the cash-pay aesthetics market. Our company name is derived from the word Evolution. We’ve evolved the medical aesthetics business model by intentionally moving away from a reimbursement model and partnering with customers differently to provide greater value.
Our flagship product Jeuveau® is a proprietary neurotoxin indicated to temporarily improve the look of moderate to severe frown lines in adults. For the fourth consecutive year, Jeuveau has been the fastest growing neurotoxin in the U.S.
In 2023, Evolus entered into a licensing agreement with Symatese to bring injectable hyaluronic acid gels to market. Upon approval, these products will be commercialized under the brand name Evolysse in the United States. Evolus anticipates U.S. approval and launch of two Evolysse products in 2025.
ONE MILLION ENROLLED
CONSUMERS
Now celebrating one million consumers in Evolus Rewards, the only co-branded patient loyalty program designed to help practices grow by rewarding every patient, every time.*
EVERY TREATMENT,
EVERY TIME*
*patients eligible once every 90 days
.svg)